Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alexion | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alexion

Soliris sales up 39% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion

3Q Revenues: $555.1 million (+39%)

3Q Earnings: $177.7 million (+89%)

YTD Revenues: $1.6 billion (+48%)

YTD Earnings: $503.6 million (+85%)

Comments: Soliris sales were $555.1 million in the quarter, up 39%, driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment. R&D expenses were $100.7 million in the quarter, up 14%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters